|
Number of patients (%)
|
2716
|
453 (16.7)
|
741 (27.3)
|
1522 (56)
|
|
Female sex (%)
|
2176 (80.1)
|
325 (71.7)
|
599 (80.8)
|
1252 (82.3)
|
|
Age at treatment start (years); mean (SD)
|
59.3 (13.3)
|
61.7 (14.0)
|
60.7 (12.9)
|
57.8 (13.0)
|
|
Duration of RA at treatment start (years); mean (SD)
|
14.2 (11.4)
|
9.5 (11.1)
|
14.4 (11.8)
|
15.5 (10.8)
|
|
Intravenous treatment
|
1365 (50.3%)
|
194 (42.8%)
|
381 (51.8%)
|
790 (52.1%)
|
|
Subcutaneous treatment
|
1338 (49.3%)
|
257 (57.0%)
|
355 (48.2%)
|
726 (47.9%)
|
|
ESR (mm 1st h); median (IQR)
|
23 (11–42)
|
23 (12–42)
|
23.5 (12–40.25)
|
22 (10–41)
|
|
CRP (mg/l); median (IQR)
|
9 (3.5–23)
|
11 (5–24)
|
8 (3.48–23)
|
8 (3–22)
|
|
DAS28; mean (SD)
|
4.98 (1.29)
|
5.01 (1.23)
|
4.93 (1.28)
|
4.99 (1.31)
|
|
DAS28-CRP; mean (SD)
|
4.66 (1.13)
|
4.64 (1.14)
|
4.57 (1.13)
|
4.70 (1.13)
|
|
VAS pain (0–100); mean (SD)
|
60 (23)
|
58 (24)
|
59 (23)
|
62 (22)
|
|
VAS global (0–100); mean (SD)
|
60 (22)
|
56 (23)
|
60 (23)
|
62 (22)
|
|
Swollen joint count (0–28); median (IQR)
|
5 (2–9)
|
6 (3–10)
|
5 (2–8)
|
5 (2–9)
|
|
Tender joint count (0–28); median (IQR)
|
6 (3–10)
|
6 (2–11)
|
6 (3–10)
|
6 (3–11)
|
|
HAQ-DI (0–3); mean (SD)
|
1.32 (0.63)
|
1.16 (0.63)
|
1.30 (0.65)
|
1.37 (0.62)
|
|
Physicians global (0–4); median (IQR)
|
2 (2–3)
|
2 (2–3)
|
2 (2–3)
|
2 (2–3)
|
|
Current methotrexate
|
1288 (57%)
|
196 (55%)
|
373 (61%)
|
719 (55%)
|
|
Current glucocorticoids
|
1316 (49%)
|
176 (39%)
|
345 (47%)
|
795 (52%)
|
|
Glucocorticoids dose in mg, prednisolone equivalent; mean (SD)
|
7.5 (4.2)
|
7.6 (3.9)
|
6.9 (4.0)
|
7.8 (4.3)
|
|
Current csDMARD
|
1489 (55%)
|
237 (52%)
|
425 (57%)
|
827 (54%)
|
